IVIG for small fiber nerve pain with specific antibody tests
Part of Brain & nervous system clinical trials.
This trial studies whether IVIG (an immune therapy made from donated antibodies) can reduce pain from autoimmune small fiber neuropathy. You may be a candidate if your tests show certain autoantibodies (TS-HDS, FGFR3, or Plexin-D1) and your symptom scores are high enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have proof of small fiber neuropathy from a skin biopsy within the last 12 months (or be willing to repeat it for the study)
- Have abnormal antibody test results for TS-HDS, FGFR3, or Plexin-D1 within the last 12 months
- Have baseline nerve pain of at least 4 out of 10 on a pain scale, and other nerve symptom scores of at least 4 out of 10
- Be female who is not pregnant or breastfeeding, and agree to use 2 forms of birth control or avoid heterosexual sex during treatment
- Be able to take part safely in a study visit and follow the study plan (and understand it)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving an infusion of antibodies (called IVIG) can reduce pain in people with nerve damage that causes burning or stabbing pain. If you have painful small fiber neuropathy or sensory neuronopathy, this treatment might help calm your nerves and ease your pain.
This trial tests whether a combination of three immune-suppressing drugs (IVIg, cyclophosphamide, and methylprednisolone) given early can improve balance and sensation in people with a rare nerve condition caused by anti-Hu antibodies. The goal is to stop or slow the nerve damage before it gets worse.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This trial tests intravenous immunoglobulin (IVIG), a donated antibody treatment, for people whose gastrointestinal (GI) “motor” symptoms are not improving with standard care and may be auto-immune related. If you’re eligible, IVIG could help calm the immune system and improve gut movement symptoms.
This Phase 3 study compares different dose schedules of PANZYGA (immune-globulin) in children with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). It aims to find a dosing plan that is both safe and effective for improving symptoms and function.
This study tests whether a new immune therapy called XEMBIFY works as well as a standard treatment (Gamunex-C) for CIDP, a condition where the immune system damages nerves and causes weakness. Both are given as infusions under the skin every three weeks.
Hear when a new Small Fiber Neuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.